This extreme breadth of written prescription power at the hands of multiple specialties and the drug’s perceived versatility has made it a solid perfromer for AstraZeneca on Wall Street. Although the potential for the patients who take Seroquel to develop overt diabetes mellitus is definitely more than theoretical, the bad press its congener cousin Zyprexa has received over the issue has created and maintained the spectre of Seroquel’s relative safety among prescribing healthcare professionals. That is…until now. At issue is whether the pharma company purposefully withheld information from the public with regard to health risks similar to those known to have been caused, in part, by antispychotic medications like Zyprexa. The plaintiffs claim Seroquel caused diabetes, weight gain and related health problems, from kidney failure and heart attacks to amputations and damage to the pancreas, which makes insulin.

Meanwhile, AstraZeneca said recently that the FDA has asked for additional information about the safety and effectiveness of a newer version of the drug, the newly patented Seroquel XR extended release tablets. That version is approved for schizophrenia and bipolar disorder, but the company is seeking approval to market it for anxiety and major depression. To the pharma company, such a move to extend a patent is either one of hubris or simple denial. | LINK

Related posts:

1. Insurance Companies Increase Donations to Fight Breadth of Public Option in Reform Just because there’s a congressional recess this month doesn’t mean...
2. Pharma Company Goes on the Defensive Amid New Avandia Attacks A safety review of GSK’s Avandia, under fire and intense...
3. FDA Panel Split on Possibility of Adverse Effects of Popular Antipsychotic in Treating Depression This has to be the absolute sanest thing the FDA...